How to Read a Research Study

The ability to read a research study is the most useful skill you can develop for evaluating peptide research claims. Every pillar article on Peptidings cites primary sources—peer-reviewed papers describing the actual experiments behind the evidence. Those citations exist so readers can verify the claims themselves. But citing a paper is only as useful as the reader’s ability to evaluate what the paper actually shows.

Most people skip directly to the abstract—the 200-word summary written to present the paper’s findings as favorably as possible. Abstracts are the marketing materials of academic publishing. They emphasize positive findings, minimize limitations, and are written to maximize the chance the paper gets read and cited. Reading only abstracts is how people end up with confident beliefs about compounds that the underlying studies do not actually support.

This guide is a systematic approach to reading a primary research paper critically. It covers each section of a typical paper in order, explains what to look for and what questions to ask, addresses the statistical concepts that matter for evaluating peptide research, and describes the most common ways that valid studies produce findings that are misleadingly interpreted. It is written for an intelligent non-expert reader—no statistical training required, but the willingness to slow down and think critically is essential.

Before You Start: Orient Yourself

Before reading a paper, spend 60 seconds orienting yourself to its context. Ask three questions:

Who did this research? What institution or company funded it? Who are the authors and what are their affiliations? This context matters for interpreting what follows—not because affiliated researchers are necessarily biased, but because knowing the institutional and funding context helps you apply appropriate skepticism when results look unusually clean or favorable.

Where was it published? Is this a peer-reviewed journal? What is the journal’s subject area and general reputation? Preprints (papers posted before peer review, typically on servers like bioRxiv or medRxiv) have not been reviewed by independent experts—they represent preliminary findings that may change substantially before formal publication. A paper in a high-impact specialty journal underwent more rigorous peer review than a paper in a low-tier general journal. Not all published science is equally scrutinized.

When was it published? Research exists in a temporal context. A 2005 rodent study represents the state of knowledge as of 2005; subsequent research may have confirmed, contradicted, or recontextualized it. The most recent studies in a field generally have the most complete picture of where the evidence stands.

Title and Abstract: How Not to Be Misled

Academic paper titles and abstracts are written to attract readers, citations, and media coverage. This creates systematic incentives toward positive framing that can mislead readers who do not read further.

What Titles Overstate

Paper titles frequently omit the context that would qualify their claims. A title reading “BPC-157 Promotes Tendon Healing in Rats” may accurately describe the study’s finding while omitting that this was in 6 rats over 2 weeks, using doses that are not translatable to humans, with the outcome measured by a histological score that does not directly correspond to functional healing. None of these details are false or hidden—they are in the paper. But the title does not communicate them, and for most readers the title is all they see.

Common title patterns to read carefully: any claim about “promoting,” “enhancing,” or “accelerating” without specifying the population (in vitro? rodent? human?); any comparison claim (“superior to standard treatment”) without specifying the study size and design; and any translational language (“potential treatment for”) that implies human applicability from non-human data.

Reading the Abstract Correctly

The abstract is a structured summary with four conventional sections: background, methods, results, and conclusions. The methods section of the abstract is the most important and the most commonly skimmed. Before accepting the results and conclusions, read the methods summary carefully. It typically tells you: what kind of study this was (human trial, animal study, cell culture), how many subjects were enrolled, what the primary outcome was, and how long the study ran. These four pieces of information determine whether the results are meaningful for the question you are trying to answer.

A specific abstract-reading skill: compare the claims in the conclusions section against what was actually measured in the methods. Authors sometimes write conclusions that are broader than their results support. “This study demonstrates the therapeutic potential of X for Y” may be the conclusion of a study that showed a statistically significant improvement in a biomarker—not a clinical outcome—in 20 rats over 4 weeks. The biomarker finding is real; “therapeutic potential for Y” is an interpretation that goes beyond what was measured.

Methods: Where the Real Story Lives

The methods section is where study quality is determined. It is also the section that takes the most effort to read and is most often skipped. Do not skip it. The specific questions to answer from the methods section:

What Was the Study Population?

Who or what received the intervention? The answer profoundly affects what the results mean for human applications. A study in healthy young mice has different implications than a study in aged mice with induced disease—even if both test the same compound at the same dose. A study in dialysis patients with specific kidney disease has different implications than a study in generally healthy adults. The population specificity of a finding is one of the most commonly overlooked qualifications in evidence interpretation.

What Was the Control Condition?

A control group is the comparison against which the treatment effect is measured. Without a control, you cannot distinguish the compound’s effect from the natural history of the condition, regression to the mean (the tendency of extreme measurements to move toward average on remeasurement), placebo effects, or seasonal and environmental variation. Studies without control groups produce observations—valuable for hypothesis generation, not for establishing that a compound causes an effect.

Types of control conditions to note: untreated controls (no intervention), vehicle controls (the solvent used to dissolve the compound, without the compound—important for ruling out solvent effects), positive controls (a known-effective treatment used as a benchmark), and placebo controls in human studies (inert treatment given to the control group). The strongest design is a randomized, double-blind, placebo-controlled trial—in which neither the participants nor the researchers assessing outcomes know who received treatment until the analysis is complete.

What Was the Primary Endpoint?

The primary endpoint is the specific outcome the study was designed and powered to measure. It should be stated explicitly in the methods section, ideally with reference to a pre-specified trial registration (for human clinical trials). The primary endpoint is the finding that carries the most statistical weight—it was determined before data collection, the sample size was calculated based on detecting a meaningful effect on this specific outcome, and it is the least susceptible to the multiple comparison problem discussed below.

Secondary endpoints are additional outcomes measured alongside the primary endpoint. They are exploratory—they generate hypotheses for future studies. A study that fails its primary endpoint but shows positive results on secondary endpoints has produced a negative result with some interesting signals, not a positive result. This distinction is routinely violated in popular coverage of research and in community discussions of peptide studies.

What Was the Dose and Route?

For peptide research specifically, the dose and route of administration in a study are critical to interpreting whether the results are relevant to a specific application. A compound that shows efficacy at 10 mg/kg intraperitoneal injection in mice is not the same as showing efficacy at a subcutaneous human dose—the route changes absorption and distribution, and the allometric scaling from rodent to human dose is not a simple multiplication. Both the dose magnitude and the administration route must map to the intended application for preclinical evidence to be meaningful for that application.

Study Types: What Each Design Can and Cannot Prove

In Vitro (Cell Culture) Studies

In vitro studies examine the effects of a compound on cells or tissues in a laboratory dish or flask. They are the right tool for mechanistic investigation: showing that a compound interacts with a specific receptor, inhibits a specific enzyme, or changes gene expression in a specific cell type. They are not appropriate for drawing conclusions about what the compound does in a living organism.

The critical limitation: cells in culture exist outside their normal physiological context. They lack the blood supply, immune system, competing signaling pathways, and metabolic processing of a whole organism. Concentrations that produce effects in vitro are frequently unachievable in vivo without toxicity. Compounds that kill cancer cells in a dish have a long history of failing in animal models and human trials because the in vitro concentration required is not achievable in a living person without systemic toxicity.

Animal Model Studies (In Vivo Preclinical)

Animal models are more informative than cell culture for whole-organism pharmacology—absorption, distribution, metabolism, and elimination (ADME) are all present, and the compound must survive real physiological conditions to produce effects. Well-designed, well-validated rodent models of specific diseases can produce results that are genuinely predictive of human responses, though the track record of translation is substantially below 100%.

The key questions for an animal study: What model was used, and how well validated is it for the specific human condition being studied? Mouse colitis models share some features with human IBD but differ in important mechanisms—this is why VIP works in every mouse colitis model but has not completed a human IBD trial. What was the dose, and how was it calculated? Was the study blinded (did the researchers assessing outcomes know which animals received treatment)? Unblinded animal studies systematically show larger treatment effects than blinded ones.

Human Clinical Trials

Clinical trials are covered in depth in the Evidence Levels guide. The key distinctions relevant to reading a specific trial paper: Phase I establishes safety, not efficacy. Phase II is exploratory—positive results are promising but not conclusive. Phase III is the definitive trial, but only if it was adequately powered, properly randomized, double-blinded where possible, and had a pre-specified primary endpoint that it met. A Phase III trial that meets its primary endpoint in a well-designed, pre-registered study is the gold standard of clinical evidence. A Phase II trial showing a positive biomarker effect in 40 patients is a much more tentative signal, however compelling it may seem.

Results: Reading Numbers Correctly

The results section presents the data. Reading it correctly requires distinguishing between the primary endpoint, secondary endpoints, and post-hoc analyses; between absolute and relative effect sizes; and between statistical significance and clinical significance.

Absolute vs. Relative Effect Sizes

This distinction is among the most commonly exploited sources of confusion in medical research communication. A treatment that reduces an outcome from 2% to 1% has produced a 50% relative risk reduction—and a 1 percentage point absolute risk reduction. Both statements are accurate; they create very different impressions.

For peptide research, always look for the absolute change in the measured outcome. If a study reports that BPC-157 “reduced inflammatory markers by 40%,” the meaningful question is: from what baseline, and was the absolute change large enough to matter biologically? An inflammatory marker that dropped from 10 units to 6 units (a 40% reduction from a mildly elevated baseline) means something different than one that dropped from 100 units to 60 units in a severely inflamed model.

Surrogate Outcomes vs. Clinical Outcomes

Surrogate outcomes are measurable biological markers that are assumed to correlate with clinical outcomes. Inflammatory cytokine levels, biomarker concentrations, histological scores, and imaging findings are all surrogates. Clinical outcomes are what actually matters to patients: whether they recovered faster, had less pain, lived longer, or functioned better.

Surrogate outcomes can be improved by a compound without any improvement in clinical outcomes—and occasionally, improving a surrogate worsens clinical outcomes (this happened famously with antiarrhythmic drugs that improved cardiac biomarkers but increased mortality). For a compound’s effects to matter clinically, they must ultimately be demonstrated at the level of clinical outcomes. In peptide research, the vast majority of evidence is at the surrogate or biomarker level.

Statistics Without a Statistics Degree

You do not need to understand the mathematics of statistics to apply the key concepts. You need to understand what the numbers mean in plain language.

The p-Value: What It Is and What It Isn’t

The p-value is the probability of observing results at least as extreme as those in the study if there were truly no effect—that is, if the null hypothesis were true. A p-value of 0.05 means there is a 5% probability that the observed result occurred by chance alone under the null hypothesis.

What p < 0.05 does NOT mean: it does not mean there is a 95% probability that the treatment works. It does not mean the effect is large or clinically meaningful. It does not mean the result will replicate. It does not mean the study was well-designed. Statistical significance and practical significance are different things, and p < 0.05 only speaks to the former.

A result can be statistically significant (p < 0.05) and clinically meaningless if the effect size is trivially small in a large sample. A result can be clinically important and statistically non-significant if the sample was too small to detect the real effect reliably. The p-value alone tells you less than most people think.

Confidence Intervals: More Informative Than p-Values

A confidence interval (CI) is a range of values within which the true effect is likely to lie. A 95% CI means that if the study were repeated many times, 95% of the calculated intervals would contain the true effect. Confidence intervals tell you both the magnitude of the effect and how precisely it is estimated.

A narrow CI (e.g., “the treatment reduced the outcome by 3.2 points, 95% CI: 2.8–3.6”) indicates a precisely estimated effect. A wide CI (e.g., “the treatment reduced the outcome by 3.2 points, 95% CI: 0.1–6.3”) indicates high uncertainty—the true effect could be trivially small or quite large, and a study with this CI is underpowered for the question it is asking. Always look for confidence intervals in addition to p-values.

The Multiple Comparisons Problem

If you test enough outcomes in the same dataset, some will achieve statistical significance by chance alone—even if there is no real effect. At a p < 0.05 threshold, testing 20 independent outcomes will produce on average one false positive purely by chance. Studies that measure dozens of outcomes (cytokine levels, biomarkers, histological parameters, behavioral measures) and report only the ones that achieved significance are producing misleading results regardless of their statistical methods.

Pre-registration addresses this: when a trial registers its primary endpoint before data collection, post-hoc selection of favorable endpoints is prevented. Look for pre-registration references in clinical trial methods (ClinicalTrials.gov registration numbers). For animal studies and in vitro work, pre-registration is rare and the multiple comparisons problem is correspondingly more prevalent.

Sample Size and Statistical Power

Statistical power is the probability that a study will detect a real effect if one exists. An underpowered study—one with too few subjects to detect the expected effect reliably—has a high false negative rate (it will frequently miss real effects) and, counterintuitively, also tends to produce inflated effect size estimates when it does find a positive result. This is because in a small sample, only studies that happened to see a larger-than-average effect will achieve statistical significance—and those effects are then published, biasing the literature toward overestimating effect sizes.

For animal studies, a group size of 6–10 animals per group is common and often adequate for the effect sizes seen in pharmacological research. For human clinical trials, adequate power typically requires several hundred to thousands of participants depending on the expected effect size and primary endpoint. A human trial with 20 participants is almost certainly underpowered for any clinically relevant endpoint.

Discussion and Limitations: What the Authors Admit

The discussion section is where authors interpret their results, place them in the context of existing literature, and acknowledge the study’s limitations. Read the limitations subsection carefully—it is one of the most useful parts of any paper and is often the most honest.

Authors who acknowledge specific, substantive limitations are giving you information about how much weight to place on their findings. Common limitations in peptide research papers: small sample size; use of animal models with acknowledged differences from human physiology; short study duration that may not capture long-term effects; use of disease-induction models that incompletely recapitulate human disease; dose and route discrepancies from what is used in human applications; single institution or single investigator group; and absence of mechanistic confirmation that the observed effects were caused by the stated pathway.

A limitations section that simply states “further research is needed” without identifying specific methodological weaknesses is not a useful limitations section—it is a formality. Honest, substantive limitations sections are a marker of scientific rigor, not a weakness in the paper.

The discussion section is also where the scope creep happens. Authors move from “we observed X in this specific model at this specific dose” to “this suggests potential therapeutic applications in humans” in a few sentences. This transition is often made in ways that are defensible but that overstate the translational implications of preclinical data. Read these transitions critically: is the leap from the data to the implication justified, or is it plausible speculation presented as near-established fact?

Funding, Conflicts of Interest, and Publication Bias

Funding Source Effects

Industry-funded research has historically produced more favorable results for the sponsor’s product than independently-funded research of the same products. This is not necessarily fraud—it is a combination of study design choices, endpoint selection, and publication decisions that collectively bias toward positive results. Meta-analyses across pharmaceutical research consistently show effect sizes approximately 30–40% larger in industry-funded trials than in independently-funded trials.

Knowing the funding source does not tell you the result is wrong. It tells you to apply appropriate additional scrutiny to the study design and to weight the results somewhat lower in your overall assessment of the evidence. A single industry-funded trial showing impressive results should be weighted less heavily than the same finding replicated by independent academic groups.

Publication Bias

Publication bias is the tendency for positive results to be published and negative results to go unreported. Studies showing that a compound works are more likely to be submitted, accepted, and published than studies showing that a compound does not work. This means the published literature systematically overstates the evidence in favor of interventions across all of medicine—not just peptide research.

The practical implication: a literature search that finds five studies showing positive effects of a compound does not mean five studies were done and all showed positive results. There may be ten other studies sitting in file drawers because they showed no effect. Clinical trial registries (ClinicalTrials.gov) address this for human trials by requiring registration before study initiation, allowing identification of registered trials that never published results. For preclinical research, this tool does not exist, and publication bias is correspondingly harder to assess.

Replication, Consensus, and When One Study Means Something

The most common error in interpreting research is treating a single study as establishing a fact. Individual studies—even well-designed ones—are preliminary. They generate findings that require independent replication before they can be considered reliable. This is not a counsel of paralysis; it is an accurate description of how science works.

A finding becomes more reliable when it has been independently replicated in different laboratories, using different study populations, in different experimental systems, and ideally with slightly different methodologies—because convergent evidence from multiple approaches is more robust than a single consistent finding from a single approach. BPC-157’s rodent injury data, for example, is substantially more credible than most other preclinical peptide evidence precisely because multiple independent research groups have replicated the core findings across different injury types and animal models.

The corollary: a striking positive finding from a single group, not yet replicated, should be treated as hypothesis-generating. This applies equally to compelling positive results and to concerning negative or safety findings. A single rat study showing a worrying effect of a compound is not sufficient evidence to conclude the compound is dangerous—but it is sufficient reason to look carefully at the broader evidence base before dismissing the concern.

Scientific consensus—when it exists—represents the collective judgment of researchers who have evaluated the full body of evidence over time. For most of the compounds covered on Peptidings, no meaningful scientific consensus exists because the evidence base is too limited. Where it does exist (semaglutide’s efficacy for weight loss, for example), the consensus reflects an accumulation of evidence from multiple large trials, not a single study.

Critical Reading Checklist

Run through these questions for any paper you are evaluating:

Frequently Asked Questions

Where can I find the full text of research papers?

PubMed (pubmed.ncbi.nlm.nih.gov) indexes most biomedical literature and links to abstracts for all papers. Full text is freely available for papers published with open access—typically papers funded by NIH or other government agencies, or papers in open access journals. For papers behind a paywall, many authors will provide full text on request by email (this is standard practice in academic publishing). The preprint servers bioRxiv and medRxiv host pre-publication versions of many recent papers. Google Scholar also indexes many papers and often finds freely available versions.

The study I’m reading is in rats. How should I weight it?

Animal model evidence is the appropriate starting point for evaluating mechanism and biological plausibility—it tells you what the compound does in a living system and whether its pharmacological activity justifies moving to human study. For predicting what will happen in humans specifically, rodent evidence provides a prior probability, not a definitive answer. Compounds that work well in rodents have about a 10–20% chance of making it through human clinical development to approval, varying by therapeutic area. Weight rodent evidence as meaningful but not determinative, and always note whether the model used is validated for the specific human condition of interest.

I found a paper with p < 0.001 showing a big effect. Isn’t that definitive?

Not alone. A highly significant p-value indicates the result is unlikely to be due to chance in that specific study. It says nothing about whether the study design was appropriate, whether the endpoint was pre-specified, whether the effect size is clinically meaningful, or whether the finding will replicate. P < 0.001 in an underpowered study with a post-hoc endpoint in 10 rats is worth less than p = 0.04 in a well-powered, pre-registered human trial with a validated clinical endpoint. Always evaluate the design before the statistics.

Is a peer-reviewed paper automatically trustworthy?

Peer review is a quality filter, not a quality guarantee. Peer reviewers catch obvious methodological errors, logical inconsistencies, and unsupported claims—but they work from the information provided in the paper and cannot audit the raw data or verify the experimental conditions. Published papers have been retracted for fabricated data, statistical errors, and undisclosed conflicts of interest that passed peer review. Peer review raises the probability that a paper meets basic methodological standards; it does not guarantee the findings are correct or will replicate.